North America Inhaled Nitric Oxide Market Size, Share, 2026

North America Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Country, Industry Analysis and Forecast, 2020 - 2026

Published Date: March-2021 | Number of Pages: 57 | Format: PDF | Report ID: KBV-14532

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Inhaled Nitric Oxide Market, by Application
1.4.2 North America Inhaled Nitric Oxide Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies deployed in Inhaled Nitric Oxide Market – Global

Chapter 4. North America Inhaled Nitric Oxide Market by Application
4.1 North America Neonatal Respiratory Treatment Repellent Market by Country
4.2 North America Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country
4.3 North America Acute Respiratory Distress Syndrome (ARDS) Market by Country
4.4 North America Other Applications Market by Country

Chapter 5. North America Inhaled Nitric Oxide Market by Country
5.1 USA Inhaled Nitric Oxide Market
5.1.1 USA Inhaled Nitric Oxide Market by Application
5.2 Canada Inhaled Nitric Oxide Market
5.2.1 Canada Inhaled Nitric Oxide Market by Application
5.3 Mexico Inhaled Nitric Oxide Market
5.3.1 Mexico Inhaled Nitric Oxide Market by Application
5.4 Rest of North America Inhaled Nitric Oxide Market
5.4.1 Rest of North America Inhaled Nitric Oxide Market by Application

Chapter 6. Company Profiles
6.1 Getinge AB
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Merck Group
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Halma PLC
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Linde PLC (Praxair, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Acquisition and Mergers:
6.5 Air Liquide S.A.
6.5.1 Company Overview
6.5.1 Financial Analysis
6.6 Beyond Air, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expense
6.6.4 Recent strategies and developments:
6.6.4.1 Trials and Approvals:
6.7 Mallinckrodt PLC (International Minerals and Chemical Corporation)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Trials and Approvals:
6.7.5.2 Partnerships, Collaborations, and Agreements:
6.8 VERO Biotech LLC
6.8.1 Company Overview
6.8.2 Recent strategies and developments:
6.8.2.1 Trials and Approvals:
6.9 Nu-Med Plus, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations, and Agreements:
6.10. Novoteris, LLC
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Trials and Approvals:

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities